Asia-Pacific Preclinical Imaging Market, By Product (Systems and Services), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, and Preclinical CT Contrast Agents), Application (Research and Development, Drug Discovery, Bio-Distribution, Cancer Cell Detection, Bio-Markers, and Others), End User (Contract Research Organization, Pharmaceutical & Biotech Companies, Academic & Government Research Institutes, Diagnostics Center, and Others) - Industry Trends and Forecast to 2030.
Asia-Pacific Preclinical Imaging Market Analysis and Size
The Asia-Pacific preclinical imaging market is the industry involved in providing imaging solutions and technologies for conducting research and experimentation on animals (usually rodents) in the preclinical stage of drug development and medical research. These imaging techniques are crucial for assessing the safety and efficacy of potential drug candidates and medical treatments before they advance to clinical trials involving human subjects. Preclinical imaging allows researchers and pharmaceutical companies to evaluate the effects of drug candidates on living organisms before moving to human trials. This helps in identifying potential issues, optimizing dosage regimens, and reducing the risk of adverse effects in later stages.
Data Bridge Market Research analyzes that the Asia-Pacific preclinical imaging market is expected to reach the value of USD 396,436.69 thousand by 2030 from USD 264,195.80 thousand in 2022, at a CAGR of 5.5% during the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Product (Systems and Services), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, and Preclinical CT Contrast Agents), Application (Research and Development, Drug Discovery, Bio-Distribution, Cancer Cell Detection, Bio-Markers, and Others), End User (Contract Research Organization, Pharmaceutical & Biotech Companies, Academic & Government Research Institutes, Diagnostics Center, and Others)
|
|
Countries Covered
|
Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific
|
|
Market Players Covered
|
PerkinElmer Inc., FUJIFILM Visualsonics, Inc (A Subsidiary of FUJIFILM Corporation), Bruker, Hologic, Inc., ZEISS Group, Agilent Technologies, Inc., Hamamatsu Photonics K.K., Vieworks Co., Ltd., LI-COR, Inc., Berthold Technologies GmbH & Co.KG, MILabs B.V., Trifoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, AI4R and among others
|
Market Definition
Preclinical imaging is the use of various imaging techniques and technologies to visualize and study biological processes, diseases, and drug responses in animal models before they are tested in humans. It involves the non-invasive imaging of animals, typically rodents, such as mice and rats, to gain insights into the underlying mechanisms of diseases and to evaluate the efficacy and safety of potential therapies.
Asia-Pacific Preclinical Imaging Market Dynamics
Drivers
- Increasing Technological Advancement in the Field of Imaging
Technology advancement in the field of imaging is playing a crucial role in driving the growth of the Asia-Pacific preclinical imaging market. Modern imaging technologies, such as high-resolution magnetic resonance imaging (MRI), micro-computed tomography (micro-CT), and advanced ultrasound provide researchers with clearer and more detailed images of biological structures.
Furthermore, there have been significant improvements in image analysis and data processing algorithms. Advanced software tools and machine learning algorithms enable researchers to extract quantitative data from images, automate image processing tasks, and improve the accuracy and efficiency of data analysis. These advancements save time and enhance the reproducibility and reliability of preclinical studies.
- Increasing Number of Investments and Funding in Research and Development
The increasing number of investments and funding in research and development (R&D) is a significant driver of the growth of the Asia-Pacific preclinical imaging market. Organizations are allocating substantial resources to advance imaging technologies and support innovative research initiatives as the importance of preclinical imaging in drug discovery and development becomes more evident.
Investments and funding in R&D enable the development of novel preclinical imaging modalities and techniques. This financial support facilitates the improvement of imaging systems, software, and hardware, leading to enhanced image quality, resolution, and sensitivity. These advancements enable researchers to obtain more accurate and detailed information about biological processes, disease mechanisms, and treatment responses, driving the growth of the preclinical imaging market.
Opportunity
- Increasing Adoption of Imaging Systems for Preclinical Purpose
The pharmaceutical and biotechnology industries are continually searching for novel drug candidates to address unmet medical needs. Preclinical imaging allows for a more comprehensive understanding of potential drug candidates by visualizing their effects on living organisms. This helps in identifying promising candidates and eliminating those with unfavorable characteristics earlier in the drug development process, saving time and resources. The shift toward personalized medicine requires a more thorough understanding of individual patients' conditions. Preclinical imaging can be used to assess disease heterogeneity and tailor treatment approaches, leading to more effective therapies.
Restraint / Challenge
- Stringent Regulatory Framework for Product Approval
Regulatory bodies around the world have established strict guidelines and requirements for the approval of preclinical imaging products, which can create barriers for companies in the market and is a significant restraint factor on the growth of the Asia-Pacific preclinical imaging market.
The regulatory process for preclinical imaging products is a time-consuming and expensive. Companies conduct comprehensive studies to demonstrate the safety and efficacy of their products, which involves significant investment in research and development. In addition, the regulatory submission process requires extensive documentation, data analysis, and interaction with regulatory authorities, all of which add to the time and cost burden.
Recent Developments
- In November 2022, Bruker announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. This helped the organization develop more revenue
- In May 2022, FUJIFILM Corporation announced the launch of Vevo F2, the world’s first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The Vevo F2 features HD image processing technology and introduces a completely new signal pathway – from transducer to display screen. This enabled better image clarity, and when combined with multi-line processing, delivers significantly improved frame rates over earlier generation platforms
Asia-Pacific Preclinical Imaging Market Scope
The Asia-Pacific preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Systems
- Services
On the basis of product, the market is segmented into systems, and services.
Reagents
- Preclinical Optical Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
On the basis of reagents, the market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents.
Application
- Research and Development
- Drug Discovery
- Bio-Distribution
- Cancer Cell Detection
- Bio-Markers
- Others
On the basis of application, the market is segmented into research and development, drug discovery, bio-distribution, cancer cell detection, bio-markers, and others.
End User
- Contract Research Organization
- Pharmaceutical & Biotech Companies
- Academic & Government Research Institutes
- Diagnostics Center
- Others
On the basis of end user, the market is segmented into contract research organization, pharmaceutical & biotech companies, academic & government research institutes, diagnostics center, and others.
Asia-Pacific Preclinical Imaging Market Regional Analysis/Insights
The Asia-Pacific preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user.
The countries covered in this market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific.
China is expected to dominate the market due to growing demand for imaging devices. China is the fastest growing country in the market with the largest market share due to rising technological advancements.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from regional brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Preclinical Imaging Market Share Analysis
The preclinical imaging market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the Asia-Pacific preclinical imaging market are PerkinElmer Inc., FUJIFILM Visualsonics, Inc (A Subsidiary of FUJIFILM Corporation), Bruker, Hologic, Inc., ZEISS Group, Agilent Technologies, Inc., Hamamatsu Photonics K.K., Vieworks Co., Ltd., LI-COR, Inc., Berthold Technologies GmbH & Co.KG, MILabs B.V., Trifoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, AI4R and among others.
SKU-